Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gonna make a comeback any day now. Amazon is going to spinoff it's delivery service into ANTH's shell.
Wow, 7.143-Bagger Huge rally from 0.0070 to 0.05 without any good news at all! Why such strong rally?
Why ANTH crashed to 0.023 last session (on this Monday) or a day ago? Will its New Bottom 0.0070 be tesed again very soon?
0.0001 very soon? Why? Anyway ANTH only crashed to 0.0070 so far!
LOL, How could this Pos Scam crash back to 0.035 from yesterday's high 0.07 which is 50% decline without any Bad News at all?
ANTH crashed to 0.028 yesterday with Tens Of Thousands shares! It will test its current Bottom $0.0070 again as soon as this month though it has already bounced to 0.0700 yesterday...
New 52-week low 0.0070 was created! How could this Pos Scam be able to bounce 10-Bagger+ to 0.07+? Anyway it just crashed to 0.03 again... Sell ASAP since it will hit 0.01 very soon!
Those emotional most recent 0.399 ~ 0.1 buyers are in Hyper Deep Losses now and they have to cut their Giant losses before the end of 2018 which will soon drive this Pos Scam down to 0.001 ~ 0.01 area! Very soon even those 0.0999 ~ 0.07 buyers will incur huge losses too once 0.07 is broken down!
Why a worthless junk stock is trading at $2.592M ~ $1.833M MV now? Which is ridiculous high and not sustainable because its OTC peer (such as URBF) is trading at $0.016M MV or $0.0001 a share now! Which means ANTH is 162 ~ 115 Times more expensive than its peer!
When the CH7 Bankruptcy is filed with ANTH we'll see 0.0001 at the end! I've been very busy to sell out all my shares (1.5M) at 0.09xx or even 0.08xx to make huge quick gain before the death spiral kicks in which will destroy ANTH to as low as 0.0010...
No any value left! Worthless junk stock with a crap CEO and the worst management team! They have stolen all the potential value long time ago... I'll sell out all my remaining shares at 0.099 ~ 0.09 or even 0.08xx again if there is no way to get rid of this Pos Scam at 0.09xx...
ANTH will soon crash to 0.01 ~ 0.0010 price levels before the end of 2018...
They still have some pretty valuable IP and another drug in the pipeline right?
De-registration is just to cut costs. I don't own any of this, but seems like there might be value here.
The Form 15-12b was just filed yesterday after the market close! Which means no more filing in the future and ANTH will become a Non-Reporting OTC stock. So we should see this pos scam heading onto 0.01 or below very soon after the most recent 0.07 ~ 0.099 buyers exhaust their purchasing powers and ANTH breaks down the current bottom 0.07...
I bought back all my 1M+ shares at 0.07xx and sold partial shares at 0.099 ~ 0.08 most recently. Enjoy nice and easy quick gain from ANTH! Hopefully 0.07 could hold forever bottom for the shareholders!
I'm very glad to have made very nice initial Quick gains by selling my partial ANTH shares at 0.09xx ~ 0.08xx! I'll sell out all the remaining shares in the coming days/weeks because I'm afraid the coming Dissolution/Liquidation and Huge R/S & Diluting risks here...
I'll use all the proceeds to buy a OTCQB/NYSE stock with over 20 Times of BV/PPS ratio!
I'm very glad to have bought back my previous 1M+ shares at 0.07xx (I sold the previous position at 0.23 ~ 0.39 for huge profit)! Now I'm enjoying very nice initial gain and I'll flip out all the ANTH shares for another round of Quick huge gain as I did before De-Listing because I don't want to stuck with this Pos Scam when the coming Liquidation/Bankruptcy or Huge R/S kicks in...
Anyway Huge Dilutions are going-on here everyday and our ownership is shrank for each day! What a Giant Diluting Machine?
Another New low 0.07 was created so far! Hopefully this Pos Scam won't crash to 0.01 like its similar-SS peer did most recently...
When will the on-going Huge Dilutions be ended here? When will the Big R/S kick in? Will the company file the Bankruptcy this month? Will our common shares be Worthless very soon? Why didn't the company fire both the Useless employees and the crap CEO?
The Pos Scam is heading onto another New low $0.0596 based on its NYSE peer (RASF: 48.125% price crash with $1.59 BV and $0.91 CV) did after de-listing from NYSE to OTCQB! Because many institution shareholders will be forced to liquidate all their common shares at any price due to its current OTC-Pink-Sheet trading status (ANTH was a Nasdaq stock)!
A Series Of New 52-week lows will be created in the coming days/weeks since the on-going Huge Sell-Off will continue...
0.04 should hold the Bottom before the bounce if no any further Very Bad news like Giant Dilutions or Huge R/S or Bankruptcy Filing! Where is the crap CEO while we need him? Will the Huge R/S or Giant Dilutions kick in as soon as next week?
Those 0.18 ~ 0.1175 buyers are in Very Deep Huge Losses now and very soon those 0.117 ~ 0.0901 buyers will be the same!
I had already flipped three times for some quick gain.
Anyway I ever warned all the buyers here: don't buy ANTH above $0.31! Those $0.399 ~ $0.3101 buyers will never recover their Giant Losses in the future!
Wow, ANTH crash to 0.0755 so far! Will it crash to 0.06 as soon as today? I bet 0.04 will hold the Bottom if no any further Very Bad news like Giant Dilutions or Bankruptcy Filing! Where is the crap CEO while we need him? Will the Huge R/S kick in as soon as next week?
Yesteray's 0.0117 ~ 0.0901 buyers are in Very Deep Huge Losses now...
The Pos Scam (ANTH) just declined to another New low $0.0901 so far! I bet another New low $0.071 will be created as soon as this week because many institution shareholders will be forced to liquidate their positions due to its current OTC-Pink-Sheet trading status...
In fact the same thing happened to its NYSE peer (RASF): the institution's sell-off lead to 48.125% huge price crash --- from its previous Bottom $0.16 (as a NYSE stock) to the current new Bottom $0.083 (as a OTCQB stock)! Thus ANTH will crash to $0.0596 (as a OTCPS stock) very soon from yesterday's low $0.115 (as a Nasdaq stock)! I'm flipping for 20% quick gain now before it is too late...
I'm so dang glad that I got out of anth last week with a profit. Wheeeeew!!!
Almost exactly like I predicted a couple of weeks ago ANTH crash to $0.115 today! Tomorrow it will be traded on the OTC market. We might see A Series Of New 52-week lows tomorrow due to today's Nasdaq De-listing event!
In the worst situation we might see it further crash to 0.04 then it will bounce back to 0.2 or higher. Perhaps 0.071 will be the Lowest price it could go tomorrow if the on-going sell-off continues like today! Anyway after ANTH finds out its true New Bottom it will quickly bounce back to 0.212 or higher based on the recent bouncing patterns plus its basic valuation...
If ANTH follow its peer's performance (RASH crash to 0.083 from its previous Bottom 0.16 after De-listing from NYSE to OTCQB market) then it will crash to 0.0596 tomorrow...
Anyway I ever warned all buyers here: don't buy ANTH above $0.31!
* * $ANTH Video Chart 06-27-18 * *
Link to Video - click here to watch the technical chart video
ANTH delisted from Nasdaq to OTC effective June 28, 2018.
http://otce.finra.org/DailyList
Look it is being delisted. Good for you getting out early and catching it. Bad for everyone else still in Anthera
POS CEO and garbage company/management. I played this ticker last summer for two Pumps then got out quick before their RS and shenanigans. Sad for all those who got fleeced thinking and believing in the product(s)/.
The Pos Scam is heading onto $0.10xx in the coming days/weeks...
Nasdaq-Delisting will kick in anytime from now on... Usually this kind of downgrading crash the price down by -50%!
The well overdue Dissolution and Liquidation will be another very important Negative event...
ANTH President/CEO leaving - "Termination without Cause" ?
Yes. I sold out all my remaining shares today and made huge Quick profit! Be honest, today's ANTH performance is much much better than I expected (I thought $0.31 would be the top ceiling)! Congratulate to all today's and yesterday's very smart sellers who sold out this Pos Scam at Extremely Overvalued price levels! I'll buy this trash again when it hit $0.10xx after De-listing... Anyway its Bio-Tech peer (NSPR) is a much much better NYSE stock with huge upward potential plus very strong fundamentals! Another NYSE peer (RASF) is also one fire now with much much better fundamentals!
* * $ANTH Video Chart 06-12-18 * *
Link to Video - click here to watch the technical chart video
I'm assuming you sold out now?
Kline I said yesterday, this stock is going to hit .50 then run to dollars. Mark this post. Reversal is in order.
$ANTH
.50 is coming to this stock this week. This is a chart play and it's being played to the "T" by many players. Could see a buck within a week or two. This is an exciting week and will surpass .31 by leaps and bounds this week alone.
$ANTH
Glad to make huge profit today by selling out the majority of my shares today! I'll continue to sell the rest 200K+ shares tomorrow at $0.31 ~ $0.24 to get rid of ANTH because it is Extremely Overvalued now and Extremely Overbought today! Then I'll wait to buy back all the shares at $0.1xxx very soon... De-listing and Downgrading will kick in as soon as this week...
Warning to all the buyers! Any price above $0.31 is Hyper Risk which will lead to 50% or more losses in the coming days/weeks...
We breached the MA50 today, looking forward to reaching the MA100 later in the week. Got a strong feeling that we may closed that down gap on this run. We have to get to $2.50 to complete the down gap. Chart reversal in motion here. Enjoy the ride. Should see a much greater jump in price tomorrow. Volume is here and the investment community have been alerted today. Watch them pounce on this stock tomorrow.
$ANTH all indicators pointing to this stock doubling or better this week. Over a buck within the next 2-3 weeks.
Enjoy the ride.
From whatsonthorold.com
Among 7 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. Anthera Pharmaceuticals had 21 analyst reports since August 13, 2015 according to SRatingsIntel. Piper Jaffray maintained Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) rating on Thursday, December 29. Piper Jaffray has “Overweight” rating and $1.35 target. The stock has “Buy” rating by Suntrust Robinson on Wednesday, September 9. Jefferies reinitiated Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) on Friday, February 19 with “Buy” rating. The company was maintained on Monday, June 26 by Jefferies. As per Tuesday, March 6, the company rating was maintained by Jefferies. The firm has “Hold” rating by Jefferies given on Sunday, August 6. On Thursday, August 13 the stock rating was upgraded by Zacks to “Hold”. Citigroup downgraded the shares of ANTH in report on Thursday, December 29 to “Neutral” rating. The stock of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has “Buy” rating given on Wednesday, September 9 by SunTrust. Citigroup initiated the stock with “Buy” rating in Thursday, September 17 report. See Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) latest ratings:
12/03/2018 Broker: Piper Jaffray Rating: Sell Downgrade
06/03/2018 Broker: Jefferies Rating: Hold New Target: $2.0 Maintain
21/02/2018 Broker: Roth Capital Rating: Buy New Target: $10 Initiates Coverage On
13/02/2018 Broker: Jefferies Rating: Hold New Target: $1.75 Maintain
22/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company has market cap of $6.40 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. It currently has negative earnings.
The stock increased 6.30% or $0.0145 during the last trading session, reaching $0.2445. About 772,825 shares traded. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has declined 86.78% since June 10, 2017 and is downtrending. It has underperformed by 99.35% the S&P500. Some Historical ANTH News: ; 12/03/2018 – Anthera to explore options after lead drug’s trial failure; 06/03/2018 – Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria; 12/03/2018 – Anthera Pharma: Sollpura Did Achieve Secondary Endpoint of Coefficient of Nitrogen Absorption; 05/03/2018 – Anthera Pharmaceuticals 4Q Loss/Shr 73c; 12/03/2018 – Anthera Pharma: Anthera to Evaluate All Strategic Alternatives; 12/03/2018 – Anthera Pharma: Further Development of Sollpura to Be Discontinued; 05/03/2018 – Anthera Pharma: Phase 3 RESULT Study Completed Patient Dosing, Topline Data Expected March 2018; 05/03/2018 – ANTHERA PHARMACEUTICALS INC – QTRLY NET LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS $0.73; 12/03/2018 – Anthera Pharmaceuticals Plans to Evaluate the Full Data Outputs; 06/03/2018 – ANTHERA FILES PROSPECTUS FOR $100M MIXED SECURITIES SHELF
Positive earnings is expected this week, could propel this back over a buck in a hurry.
Watch a surprise pull off delaying Nasdaq delisting.
I bet $0.1 will be the new Final bottom before the company dissolution/liquidation or merger into another company even terrible Nasdaq De-listing news should not break down the rocket-hard Forever bottom $0.1! Its NYSE-peer did crash 50% anyway after the stock being downgraded to the OTCQB market from NYSE exchange.
Hopefully ANTH could hold the current temporary bottom $0.213 in the coming week so that I could sell out all my rest shares at $0.31 ~ $0.24! I'm selling my shares for nice profit to avoid the coming two terrible bad news --- Dissolution/Liquidation and OTC-Downgrading!
From www.tickerreport.com
Analysts Anticipate Anthera Pharmaceuticals Inc (ANTH) Will Announce Earnings of -$0.60 Per Share
Saturday, June 9th, 2018
Ethan Ryder
Equities analysts expect that Anthera Pharmaceuticals Inc (NASDAQ:ANTH) will post earnings per share of ($0.60) for the current quarter, according to Zacks. Zero analysts have made estimates for Anthera Pharmaceuticals’ earnings. The highest EPS estimate is ($0.55) and the lowest is ($0.64). Anthera Pharmaceuticals reported earnings per share of ($2.03) during the same quarter last year, which would indicate a positive year over year growth rate of 70.4%. The business is expected to announce its next quarterly earnings results on Wednesday, June 13th.
Receive News & Ratings for Anthera Pharmaceuticals Daily
Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
According to Zacks, analysts expect that Anthera Pharmaceuticals will report full year earnings of ($2.28) per share for the current financial year, with EPS estimates ranging from ($2.37) to ($2.19). For the next financial year, analysts expect that the firm will post earnings of ($1.78) per share, with EPS estimates ranging from ($2.02) to ($1.54). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Anthera Pharmaceuticals.
ANTH crashed to 0.236 right before the market close! Does that mean some bad news will be released on next Monday?
If the coming Nasdaq De-listing news does not kick in next week then we should see ANTH test and might break up the 20-Day MAL 0.26 which is a strong resistance since the previous bottom before very bad news was 0.2615!
IMO, there is no way to hit any price above 0.31 which is why I set up my selling target up to 0.31 from the lower end 0.23! Anything above 0.25 is a great selling price, not for buying because Liquidation or Dissolution plus De-listing will soon kick in! Not mention the on-going endless huge dilutions from the crap CEO and his insiders...
There's a $5.25 price target on $ANTH
Analysts Set Anthera Pharmaceuticals Inc $ANTH Price Target at $5.25 theolympiareport.com/?p=838550
Yes. I've made some very nice gain today by selling over 100K shares at 0.24 ~ 0.25xx... ANTH might bounce over 0.26 as soon as Monday unless Nasdaq De-listing news kicks in!
Chart reversal, expect a run back to .50 then over a buck real soon.
Lots of accumulation. Love those bottom buster charts.
$ANTH
Looks like you got your selling range for a short while.
GL
Eventually she has to go, looks to break .24 today. Looking good. Would love to see her breakout, I think it's coming next week.
$ANTH
Followers
|
57
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2495
|
Created
|
03/01/10
|
Type
|
Free
|
Moderators |
Anthera Pharmaceuticals Inc.
Nasdaq: ANTH
Contact Info
25801 Industrial Blvd, Suite B • Hayward, CA 94545
Press Contact: pr@anthera.com
Business Development: bd@anthera.com
Vendors: ap@anthera.com
Website: www.anthera.com
J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of Directors Paul F. Truex appointed as Executive Chairman of the Board Dr. Christopher Henney stepped down as Chairman ...
http://finance.yahoo.com/q?s=ANTH
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation,
including cardiovascular and autoimmune diseases. We currently have a Phase 2 clinical program, blisibimod.It was just recently approved by FDA to move into
PHASE 3
Blisibimod targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others.
It has taken the lupus research community over 50 years to produce a new therapy. Although it is now a year old, Benlysta (belimumab),
now marketed by GlaxoSmithKline and Human Genome Sciences, is the first human monoclonal antibody for the treatment
of lupus.
Benlysta had a slow take-off grossing $59.2 million in sales in the last three quarters of 2011, but it was approved in numerous
countries by year's end. Estimated sales for Benlysta in 2012 are said to be about $230 million, with first annual profits likely by 2015.
The surprisingly slow uptake of Benlysta allows for blisibimod to develop into a promising drug as
it currently has more desirable features than that of Benlysta.
Blisibimod has a dosing regimen of one injection weekly, compared to that of Benlysta which requires a
series of dosing before the maintenance dose begins. Also, Benlysta has limitations on usage pertaining to
specific patient populations and has not been studied in combination with other biologics.
These attributes of blisibimod including a different mechanism of action, will set it apart from
Benlysta, Global Data concludes.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |